Corporate Governance of Business Organizations in the People's Republic of China: The Legal Framework After the Revision of the Company Law in 2005

Pißler, Knut Benjamin; Liu, Junhai

doi:10.2139/ssrn.1695888

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug markets exist for illegal, low-level redundant construction; disordered market order; and consumers' single access to corporate information channels [47], which seriously affect the transparency of basic corporate information. erefore, according to the existing research and Articles 7, 14, 42, and 70 of the Drug Administration Law of the People's Republic of China, the basic information of the enterprise is divided into four third-level indexes: pharmaceutical production license information, pharmaceutical business license information, basic situation of the Board of Supervisors members, and the integrity of other employees [48,49].…”

Section: Enterprise Basic Informationmentioning

confidence: 99%

Empirical Study on the Transparency of Security Risk Information in Chinese Listed Pharmaceutical Enterprises Based on the ANP-DS Method

Wang

Guo

Chen

2020

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Frequent outbreaks of drug safety incidents pose a massive threat to public health and safety, while the transparency of security risk information in medical enterprises is not optimistic. Therefore, this study uses the analytic network process (Dempster-Shafer method) to construct a transparent comprehensive evaluation model for security risk information in listed pharmaceutical enterprises from the perspective of government supervision and listed pharmaceutical enterprises. On the basis of 59,305 data obtained by 303 enterprises listed in the Chinese biomedical sector, this research conducted an empirical study on the transparency of safety risk information in Chinese listed pharmaceutical enterprises. The current study found that the transparency of security risk information in Chinese listed pharmaceutical enterprises is generally between “general” and “relatively good” and tends to be “relatively good.” However, administrative punishment information, adverse drug reaction reporting systems, and production processes need continuous improvement.

show abstract

Section: Enterprise Basic Informationmentioning

confidence: 99%